Clinical Research Directory

Inclusion Criteria: * Subjects voluntarily participate in clinical studies. * Age 18-65 years. * Adequate organ function at screening. * Clinical laboratory values meet criteria at screening visit. r/r SLE: * Patients meet the 2019 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) OR 2012 Systemic lupus international collaborating clinics (SLICC) classification criteria for SLE at least 6 months before screening. * At screening, antinuclear antibody, and/or anti-dsDNA antibody, and/or anti-Smith antibody should be positive. * Fulfill relapsed/refractory SLE conditions. r/r IgG4-RD： * Patients meet the 2019 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for IgG4-RD. * Fulfill relapsed/refractory IgG4-RD conditions. * Patients have active disease: IgG4-RD Response Index (RI) ≥2. Progressive MS： * Diagnosis of MS according to 2017 revised McDonald criteria. * Progressive MS according to clinical course criteria revised in 2013. * Presence of Cerebrospinal fluid (CSF) oligoclonal bands (OCBs) or elevated IgG Index at screening. r/r MG： * Diagnosis of MG. * Myasthenia Gravis Foundation of America (MGFA) Class II-IV. * Positive AChR-IgG or MuSK-IgG at screening. * Fulfill refractory MG conditions. Exclusion Criteria: * Active infections such as hepatitis and tuberculosis. * Coexist other autoimmune or inflammatory diseases. * Severe underlying diseases such as tumor, uncontrolled diabetes and severe heart diseases. * Female subjects who are pregnant, breastfeeding, or planning to become pregnant while participating in this study or within 1 year of receiving LVIVO-TaVec400 treatment.